<DOC>
	<DOCNO>NCT01113983</DOCNO>
	<brief_summary>A single arm , prospective multicenter non-randomized pivotal clinical trial evaluate Edwards SAPIEN XT™ transcatheter heart valve ( model 9300TFX ) , NovaFlex™ transfemoral delivery system , Ascendra2™ transapical delivery system crimper accessory . The trial include premarket pivotal cohort evaluate system performance well post market clinical follow-up phase involve long term follow-up patient evaluate safety investigational device 5 year .</brief_summary>
	<brief_title>Transfemoral &amp; Transapical Placement Aortic Balloon Expandable Transcatheter Valves Trial ( JAPAN )</brief_title>
	<detailed_description>Purpose : To evaluate safety efficacy THV-9300 patient severe symptomatic aortic stenosis attribute calcification degeneration valve leaflet undergo surgery safely would difficult . Enrollment : 69 patient Transfemoral approach : 42 patient ( No . patient need : 23 ) Transapical approach : 27 patient ( No . patient need : 19 ) Follow-up : Subject data collection include clinical information baseline index procedure . Subjects undergo clinical follow-up discharge , 30 day , 6 month annually 5 year . Clinical site : Osaka University Hospital Kurashiki Central Hospital Sakakibara Heart Institute</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Primary : Patients judge difficult safely undergo AVR Severe senile degenerative aortic valve stenosis NYHA Functional Class II great Signed Informed Consent Primary : Aortic valve congenital unicuspid bicuspid Annulus size &lt; 18 mm &gt; 25 mm LVEF &lt; 20 %</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SAPIEN XT Valve , Cardiovascular Disease , Valvular Heart Disease , Aortic Stenosis , Heart Valve Therapy , Transapical , Transcatheter , Transfemoral</keyword>
</DOC>